CCA
TGTX icon

Column Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Column Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-750
Closed -$14K – 813
2021
Q4 		$14K Hold
750
– – ﹤0.01% 475
2021
Q3 		$25K Hold
750
– – 0.01% 362
2021
Q2 		$29K Hold
750
– – 0.01% 343
2021
Q1 		$36K Hold
750
– – 0.01% 311
2020
Q4 		$39K Hold
750
– – 0.01% 308
2020
Q3 		$20K Hold
750
– – 0.01% 360
2020
Q2 		$14K Sell
750
-374
-33% -$6.02K ﹤0.01% 431
2020
Q1 		$11K Buy
1,124
+374
+50% +$4.72K ﹤0.01% 379
2019
Q4 		$8K Buy
+750
New +$5.7K ﹤0.01% 479

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Column Capital Advisors's TGTX Position: Q1 2022 in Review

Column Capital Advisors sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 750 shares — an estimated $14K sold.

Column Capital Advisors first reported a position in TGTX in Q4 2019 and held it in 9 quarters. The position peaked at $39K in Q4 2020. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

  • Column Capital Advisors reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Column Capital Advisors sold 750 TG Therapeutics shares in Q1 2022, an estimated $14K.
  • Column Capital Advisors first reported a position in TG Therapeutics in Q4 2019 and held it in 9 quarters.
  • Column Capital Advisors's TG Therapeutics position peaked at $39K in Q4 2020.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on Column Capital Advisors's 13F filing for Q1 2022, filed 3 May 2022.